Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics is well-positioned for long-term success, with a robust pipeline of promising medications and an early approval for Lifyorli in PROC providing potential revenue growth in the near term. The recent pharmacy transition for Korlym is also expected to improve sales and patient volumes, with the potential for further upside from increased screening for hypercortisolism in larger patient populations. Overall, Corcept has shown strong financial performance and has the potential to continue delivering positive results for investors in the future.

Bears say

Corcept Therapeutics is currently facing a negative outlook due to its lack of profitability and decreasing sales projections for the future. Despite a recently increased 12-month price target of $95, the company's financial update for 1Q26 reported lower than expected revenues and a net loss per share. Additionally, there are various risks to the company's price target, including challenges in the commercial, clinical, regulatory, reimbursement, financial, legal, and intellectual property aspects of its operations.

Corcept Therapeutics (CORT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Corcept Therapeutics (CORT) has a Strong Buy consensus rating as of Jul 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.